Memo Therapeutics AG
MTx develops therapeutic antibodies for viral infections and cancer. Its proprietary DROPZYLLA® technology enables comprehensive screening of human antibody repertoires in recombinant form. Lead asset potravitug targets BK virus in kidney transplant recipients; Phase II data support a Phase III start in 2026. DROPZYLLA® also underpins MTx’s recombinant polyclonal IgG technology and the discovery of tumor-reactive antibodies from tumor-infiltrating B cells.
Category
Clinical stage development company
Title of the presentation
Translating Unique Human Immune Responses into Next-Generation Antibody Therapeutics
Speaker information
| Name | Position | Institution |
|---|---|---|
| Christoph Esslinger - Memo Therapeutics | CSO | Memo Therapeutics AG |
